Literature DB >> 32206537

A Population-Level Analysis of Pituitary Carcinoma from the National Cancer Database.

Ryan M Carey1, Edward C Kuan1, Alan D Workman1, Neil N Patel1, Michael A Kohanski1, Charles C L Tong1, Jinbo Chen2, James N Palmer1, Nithin D Adappa1, Jason A Brant1.   

Abstract

Objectives  Pituitary carcinoma is a rare entity with fewer than 200 total cases reported in the English literature. Analysis of the population-level data from the National Cancer Database (NCDB) affords the opportunity to study this poorly understood tumor type. Methods  The NCDB was queried for site, histology, and metastasis codes corresponding to pituitary carcinoma. Statistical analyses were performed to determine factors associated with overall survival (OS). Results  A total of 92 patients with pituitary carcinoma met inclusion criteria. The 1 and 5 years of OS for all patients was 93.3% (95% confidence interval [CI]: 88.2-98.6%) and 80.0% (95% CI: 71.6-89.4%), respectively. Patients with invasive primary tumor behavior had 1 and 5 years of OS of 69.2% (95% CI: 48.2-99.5%) and 52.7% (95% CI: 31.2-89.2%), respectively. Multivariate analysis demonstrated that compared with benign primary behavior, invasive behavior had increased all-cause mortality (hazard ratio [HR], 1,296, 95% CI: 15.1- > 2,000). Surgery without adjuvant radiation or chemotherapy was the most common therapy (48.9%), followed by no treatment (40.2%). Compared with surgery alone, no treatment had worse OS (HR, 11.83, 95% CI: 1.41-99.56). Increasing age and female sex were both associated with increased mortality. Conclusions  The most common treatment for pituitary carcinoma is surgery alone followed by no surgery. Surgery alone has significantly better OS compared with no treatment. The efficacy of radiation, chemotherapy, and neurohormonal treatments needs to be examined with prospective studies. © Thieme Medical Publishers.

Entities:  

Keywords:  National Cancer Database; outcomes; overall survival; pituitary; pituitary carcinoma; skull base

Year:  2019        PMID: 32206537      PMCID: PMC7082172          DOI: 10.1055/s-0039-1683435

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  23 in total

Review 1.  Clinical review: Pituitary carcinoma: difficult diagnosis and treatment.

Authors:  Anthony P Heaney
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

2.  Cancer recurrence: an important but missing variable in national cancer registries.

Authors:  Haejin In; Karl Y Bilimoria; Andrew K Stewart; Kristen E Wroblewski; Mitchell C Posner; Mark S Talamonti; David P Winchester
Journal:  Ann Surg Oncol       Date:  2014-02-07       Impact factor: 5.344

3.  Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection.

Authors:  Waseem Touma; Spencer Hoostal; Richard A Peterson; Andres Wiernik; Karen S SantaCruz; Emil Lou
Journal:  J Clin Neurosci       Date:  2017-03-11       Impact factor: 1.961

4.  SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases.

Authors:  H Bode; M Seiz; A Lammert; M A Brockmann; W Back; H-P Hammes; C Thomé
Journal:  Exp Clin Endocrinol Diabetes       Date:  2010-05-21       Impact factor: 2.949

Review 5.  Classification and pathology of pituitary tumors.

Authors:  George Kontogeorgos
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

6.  Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up.

Authors:  Gérald Raverot; Anne Wierinckx; Emmanuelle Dantony; Carole Auger; Guillaume Chapas; Laurent Villeneuve; Thierry Brue; Dominique Figarella-Branger; Pascal Roy; Emmanuel Jouanneau; Michel Jan; Joël Lachuer; Jacqueline Trouillas
Journal:  J Clin Endocrinol Metab       Date:  2010-02-17       Impact factor: 5.958

Review 7.  Long-term survival with ACTH-secreting carcinoma of the pituitary: a case report and review of the literature.

Authors:  Rita E Landman; Melvin Horwith; Ralph E Peterson; Alexander G Khandji; Sharon L Wardlaw
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

Review 8.  The epidemiology and genetics of pituitary adenomas.

Authors:  Adrian F Daly; Maria A Tichomirowa; Albert Beckers
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-10       Impact factor: 4.690

Review 9.  Pituitary carcinoma: a review of the literature.

Authors:  Brian T Ragel; William T Couldwell
Journal:  Neurosurg Focus       Date:  2004-04-15       Impact factor: 4.047

10.  Silent corticotroph carcinoma of the adenohypophysis: a report of five cases.

Authors:  Federico Roncaroli; Bernd W Scheithauer; William F Young; Eva Horvath; Kalman Kovacs; Johan M Kros; Saffa Al-Sarraj; Ricardo V Lloyd; Marco Faustini-Fustini
Journal:  Am J Surg Pathol       Date:  2003-04       Impact factor: 6.394

View more
  1 in total

Review 1.  Evolution of a refractory prolactin-secreting pituitary adenoma into a pituitary carcinoma: report of a challenging case and literature review.

Authors:  Congxin Dai; Bowen Sun; Shusen Guan; Wei Wang; Honggang Liu; Yong Li; Jialiang Zhang; Jun Kang
Journal:  BMC Endocr Disord       Date:  2021-10-29       Impact factor: 2.763

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.